Cubist says urinary tract infection drug succeeds in study

Reuters

Nov 25 (Reuters) - Cubist Pharmaceuticals Inc saidits experimental treatment for a type of urinary tract infectionshowed it was as effective as an approved antibiotic, sendingits shares up 8 percent to a 13-year high.

The main goal of a late-stage trial was to show whether theintravenous treatment, a combination of ceftolozane andtazobactam, eradicated the infection and cured patients five tonine days after the last dose.

The drug, CXA-201, is undergoing clinical development totreat gram-negative, or antibiotic-resistant infections.

"CXA-201 is one of the most critical Cubist pipeline agentsbecause of its applicability in multiple indications," AegisCapital analyst Raghuram Selvaraju said.

Massachusetts-based Cubist submitted an application tomarket tedizolid phosphate for the treatment of skin infectionslast month.

"Both CXA-201 and tedizolid phosphate could be approvedwithin the next 18 months, setting Cubist up well for thelong-term future," Selvaraju said in a note.

An estimated 2 million patients each year in the UnitedStates contract drug-resistant infections, the company said,citing a recent U.S. Center for Disease Control and Preventionreport.

CXA-201 tested the drug's efficacy in treating complicatedurinary tract infection (cUTI), an infection of the urinarysystem accompanied by an underlying condition that increases therisk of failing standard treatment.

The results of the study, showed a "statistical superiority"of the drug compared to generic antibiotic levofloxacin in 1,050patients, including those with pyelonephritis, a condition wherethe infection spreads to the kidneys.

The most commonly reported adverse events of the treatmentwere headaches, constipation, hypertension, nausea and diarrhea.

Cubist said it was concluding another late-stage study withthe drug in patients with complicated intra-abdominal infectionsand expects to report the results in late December.

CXA-201 is also being tested to treat hospital-acquiredbacterial pneumonia and ventilator-associated bacterialpneumonia, which are serious forms of lung infections.

Shares of the company were up 8 percent at $70.74 on theNasdaq in late-morning trading. They touched a high of $70.90.

View Comments (0)